Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) rose 6.8% during trading on Thursday . The company traded as high as $5.87 and last traded at $5.78. Approximately 536,071 shares changed hands during trading, a decline of 16% from the average daily volume of 636,335 shares. The stock had previously closed at $5.41.

PIRS has been the subject of a number of recent research reports. BidaskClub downgraded shares of Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 26th. HC Wainwright set a $9.00 price target on shares of Pieris Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 2nd. Four research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average target price of $9.00.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.05. Pieris Pharmaceuticals had a negative net margin of 321.83% and a negative return on equity of 180.85%. The firm had revenue of $3.93 million during the quarter, compared to the consensus estimate of $1.52 million. Pieris Pharmaceuticals’s revenue was up 400.3% on a year-over-year basis. sell-side analysts forecast that Pieris Pharmaceuticals, Inc. will post -0.72 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in PIRS. Voya Investment Management LLC purchased a new stake in Pieris Pharmaceuticals in the second quarter valued at approximately $100,000. Wells Fargo & Company MN purchased a new stake in Pieris Pharmaceuticals in the third quarter valued at approximately $105,000. State of Wisconsin Investment Board purchased a new stake in Pieris Pharmaceuticals in the second quarter valued at approximately $132,000. The Manufacturers Life Insurance Company grew its holdings in Pieris Pharmaceuticals by 1,106.3% in the second quarter. The Manufacturers Life Insurance Company now owns 31,785 shares of the biotechnology company’s stock valued at $161,000 after purchasing an additional 29,150 shares during the period. Finally, Acadian Asset Management LLC purchased a new stake in Pieris Pharmaceuticals in the second quarter valued at approximately $162,000. Hedge funds and other institutional investors own 50.59% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/16/pieris-pharmaceuticals-inc-pirs-stock-price-up-6-8.html.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Receive News & Stock Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.